LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Penumbra Inc

Gesloten

SectorGezondheidszorg

338.48 -0.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

337.48

Max

340.45

Belangrijke statistieken

By Trading Economics

Inkomsten

-176M

-130M

Verkoop

31M

385M

K/W

Sectorgemiddelde

81.89

66.845

Winstmarge

-33.822

Werknemers

4,700

EBITDA

13M

68M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+9.64% upside

Dividenden

By Dow Jones

Volgende Winsten

22 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

122M

13B

Vorige openingsprijs

339.01

Vorige sluitingsprijs

338.48

Nieuwssentiment

By Acuity

67%

33%

307 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Penumbra Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jan 2026, 13:29 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 jan 2026, 12:35 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 jan 2026, 12:29 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

25 feb 2026, 18:02 UTC

Winsten

Penumbra: Won't Be Providing Financial Guidance for 2026, Citing Proposed Boston Scientific Deal

25 feb 2026, 18:01 UTC

Winsten

Penumbra 4Q Rev $385.4M >PEN

25 feb 2026, 18:01 UTC

Winsten

Penumbra 4Q Adj EPS $1.18 >PEN

25 feb 2026, 18:01 UTC

Winsten

Penumbra 4Q EPS $1.20 >PEN

24 jan 2026, 06:18 UTC

Acquisities, Fusies, Overnames

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15 jan 2026, 14:37 UTC

Populaire aandelen

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 jan 2026, 13:45 UTC

Acquisities, Fusies, Overnames

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 jan 2026, 12:04 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 jan 2026, 12:03 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 jan 2026, 12:01 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 jan 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 jan 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Peer Vergelijking

Prijswijziging

Penumbra Inc Prognose

Koersdoel

By TipRanks

9.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 372.36 USD  9.64%

Hoogste 374 USD

Laagste 360 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Penumbra Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

15 ratings

3

Buy

12

Hold

0

Sell

Technische score

By Trading Central

288.28 / 292.9394Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

307 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat